| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 04/07/2005 | US20050075329 S-tofisopam, a prodrug or a salt thereof, free of its R enantiomer, and a carrier; may also contain one or more other anticonvulsants |
| 04/07/2005 | US20050075315 Antitumor agent |
| 04/07/2005 | US20050075313 Ophthalmic compositions containing galactomannan polymers and borate |
| 04/07/2005 | US20050075308 Methods and compositions for producing antigenic responses |
| 04/07/2005 | US20050075305 Therapeutic compositions and methods of treating glycolipid storage related disorders |
| 04/07/2005 | US20050075301 Pharmaceutical preparation with RNA as hemostasis cofactor |
| 04/07/2005 | US20050075295 Combination comprising combretastatin and anticancer agents |
| 04/07/2005 | US20050075288 Pharmaceutical and cosmetic compositions comprising plgf-1 |
| 04/07/2005 | US20050075282 inhibiting or preventing repression of neurotransmitter receptor gene expression upon or during an event causing brain injuries, using histone deacetylase inhibitors |
| 04/07/2005 | US20050075276 administering peptide or non-peptide drugs that modulate the CD28 antigen inactivation of GSK-3 in lymphocytes responses against viral, bacterial, fungal or prion infections in mammals |
| 04/07/2005 | US20050075275 Regulation of the apj receptor for use in the treatment or prophylaxis of cardiac diseases |
| 04/07/2005 | US20050075273 condensation aerosols; for treatment of pain or alcohol abuse; kits |
| 04/07/2005 | US20050075268 cell is contacted with a photosentistising agent, cell is irradiated with light to activate photosentisitising agent, the cell is contacted with the molecule to be introduced, particularly for use in cancer treatment, gene therapy and vaccination |
| 04/07/2005 | US20050074852 Serine/threonine kinase (PKN) peptides for use in identifying modulators for treatment and prevention of inflammation, cancer, arteriosclerosis and psoriasis |
| 04/07/2005 | US20050074841 DNAs encoding mammalian histamine receptor of the H4 subtype |
| 04/07/2005 | US20050074818 Methods and agents for the diagnosis and therapy of chronically inflammatory intestinal diseases |
| 04/07/2005 | US20050074770 Cloned mammalian histamine H4 receptor that couples to G-protein; for use in diagnosis, prevention and treatment of asthma, allergy, inflammation, thrombotic, cardiovascular and autoimmune disorders |
| 04/07/2005 | US20050074767 Using transcriptional activity of obesity genes as diagnostic indicator of efficacy of dietetic modulators; treating eating/weight disorders |
| 04/07/2005 | US20050074764 Using presence of point mutations in nicotinic acetylcholine receptor (nACHR) gene as diagnostic/prognosic tool in detction and treatment of indicator of cardiovascular, nervous system, vision and pain disorders |
| 04/07/2005 | US20050074761 Novel means for the diagnosis and therapy of ctcl |
| 04/07/2005 | US20050074751 Binding viral protein during latency life cycle; binding of antibodies to excellular segments of protein; immobilization; removal of infecting cells; autoimmune disease, lupus, antiarthritic agents |
| 04/07/2005 | US20050074510 Topical preparations for use in treatment of anorectal disease |
| 04/07/2005 | US20050074506 Applying energy to blood brain barrier (BBB) region to break encapsulation; activating facilitator to promote passage of therapeutic and/or diagnostic agent |
| 04/07/2005 | US20050074505 Reduced heat of hydration in wound area; adjusted calcium content; one step treatment; rapid clotting; minimizing discomfort |
| 04/07/2005 | US20050074501 Creating sterile, stable, high concentration ozone rapidly on demand; herniated discs; inflammatory and degenerative disease |
| 04/07/2005 | US20050074498 Perforated microstructure; flowability, dispersibility; stable aerosols; respiratory inhalants |
| 04/07/2005 | US20050074496 Utilizing such as fucoidan to treat surgical adhesions, arthritis, psoriasis; nontoxic, reduced side effects |
| 04/07/2005 | US20050074462 Suppressing IgE immunoglobulin mediated hypersensitivity; transdermal administration |
| 04/07/2005 | US20050074457 Simplified, high throughput screening for identification of heat shock protein 90 ligands selective for high affinity form |
| 04/07/2005 | US20050074447 Treatment for diabetic microvascular and macrovascular complications |
| 04/07/2005 | US20050074446 Gamma-tocopherol treatment for cystic fibrosis |
| 04/07/2005 | US20050074445 Alpha-tocopherol treatment for cystic fibrosis |
| 04/07/2005 | US20050074444 Nutritional supplement; aqueous emulsion containing coenzyme Q10 and solubilizer; preferably also including vitamin E, betacarotene, vitamin D and vitamin K; immunostimulation; reducing oxidative stress and respiratory complications |
| 04/07/2005 | US20050074442 Compositions and methods for augmenting kidney function |
| 04/07/2005 | US20050074440 Lactobacillus rhamnosus strain and uses thereof |
| 04/07/2005 | US20050074436 Systems and methods for treating patients with processed lipoaspirate cells |
| 04/07/2005 | US20050074429 Optimal compositions and methods thereof for treating HCV infections |
| 04/07/2005 | US20050074427 IL-17 like molecules and uses thereof |
| 04/07/2005 | US20050074426 A conjugate of a cytokine and a tumor targeting moiety with numerous provisos |
| 04/07/2005 | US20050074425 Method for delivering polymerized therapeutic agent compositions and compositions thereof |
| 04/07/2005 | DE19912850B4 Lösung, insbesondere für Hämo- oder Peritonealdialyse, sowie Verfahren zu deren Herstellung Solution, in particular for hemodialysis or peritoneal dialysis, as well as processes for their preparation |
| 04/07/2005 | DE10346083A1 Pulverförmige Zusammensetzung zur Verwendung als Laxativum Pulverulent composition for use as a laxative |
| 04/07/2005 | DE10339354A1 Synergistic composition for treating metabolic syndrome, comprises swellable or gel-forming satiating and weight reducing agent and hypocholesterolemic and/or antidiabetic agent |
| 04/07/2005 | CA2540701A1 Proteins expressed in nk cells |
| 04/07/2005 | CA2540364A1 Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers |
| 04/07/2005 | CA2540108A1 Antitumor agent_comprising a histone deacetylase inhibitor and a topoisomerase ii inhibitor |
| 04/07/2005 | CA2540056A1 Controlled release formulations of opioid and nonopioid analgesics |
| 04/07/2005 | CA2539512A1 Iloprost in combination therapies for the treatment of pulmonary arterial hypertension |
| 04/07/2005 | CA2539486A1 Methods for preparing oil bodies comprising active ingredients |
| 04/07/2005 | CA2539472A1 Ocular solutions containing a macrolide antibiotic and/or mycophenolic acid |
| 04/07/2005 | CA2538023A1 Therapeutic regimens for administering drug combinations |
| 04/06/2005 | EP1520590A1 Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases |
| 04/06/2005 | EP1520584A1 Composition for the activation of the immune system |
| 04/06/2005 | EP1520582A2 Use of dipeptidylpetidase inhibitors to regulate glucose metabolism |
| 04/06/2005 | EP1520175A2 Oncolytic viruses as phenotyping agents for neoplasms |
| 04/06/2005 | EP1520043A2 METHODS FOR THE IDENTIFICATION OF IKKa FUNCTION AND OTHER GEN ES USEFUL FOR TREATMENT OF INFLAMMATORY DISEASES |
| 04/06/2005 | EP1520042A2 Chromosome 3, 5 and 11 genes involved in premature canities |
| 04/06/2005 | EP1520032A2 Lung cancer therapeutics and diagnostics |
| 04/06/2005 | EP1520015A2 Plant deoxyribonucleoside kinase enzymes and their use |
| 04/06/2005 | EP1519957A2 Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| 04/06/2005 | EP1519956A2 Epha2 monoclonal antibodies and methods of use thereof |
| 04/06/2005 | EP1519933A1 Quinuclidine amide derivatives |
| 04/06/2005 | EP1519925A1 Oxazole derivatives and their use as insulin sensitizers |
| 04/06/2005 | EP1519923A1 Novel benzimidazol-2-one derivatives and their use |
| 04/06/2005 | EP1519922A1 Di-aryl-substituted ethane pyridone pde4 inhibitors |
| 04/06/2005 | EP1519920A1 Novel tetrahydropyridine derivatives as renin inhibitors |
| 04/06/2005 | EP1519754A1 Use of cetp inhibitors and optionally hmg coa reductase inhibitors and/or antihypertensive agents |
| 04/06/2005 | EP1519753A1 Pharmaceutical combination of a thromboxane a2 receptor antagonist and a cox-2 inhibitor |
| 04/06/2005 | EP1519752A1 Use of cetp inhibitors and antihypertensive agents as well as optionally hmg coa reductase inhibitors |
| 04/06/2005 | EP1519751A2 Compositions comprising panthetine for the treatment of dyslipidemia |
| 04/06/2005 | EP1519750A2 Oxygenating agents for enhancing host responses to microbial infections |
| 04/06/2005 | EP1519747A2 Human monoclonal antibodies to prostate specific membrane antigen (psma) |
| 04/06/2005 | EP1519744A2 Injectable solid hyaluronic acid carriers for delivery of osteogenic proteins |
| 04/06/2005 | EP1519743A1 Use of an interleukin 1 receptor antagonist and/or pyrrolidinedithiocarbamate for the treatment or prophylaxis of type 2 diabetes |
| 04/06/2005 | EP1519742A2 Osteoclast-associated receptor |
| 04/06/2005 | EP1519735A2 Assays and implements for determining and modulating hsp90 binding activity |
| 04/06/2005 | EP1519723A1 Novel glucagon antagonists/inverse agonists |
| 04/06/2005 | EP1519722A1 Glycoloyl-substituted oxazolidinone-derivatives as antibacterial agents |
| 04/06/2005 | EP1519718A1 At least partially degradable films containing an active ingredient and method for the production thereof |
| 04/06/2005 | EP1519715A2 Nanoparticulate fibrate formulations |
| 04/06/2005 | EP1480627A4 Methods of reducing angiogenesis |
| 04/06/2005 | EP1321140B1 Ibuprofen solutions for capsule-filling and capsule preparations |
| 04/06/2005 | EP1284997B1 Therapeutic compounds for ovarian cancer |
| 04/06/2005 | EP1257275B1 Use of central cannabinoid receptor antagonist for preparing medicines designed to facilitate smoking cessation |
| 04/06/2005 | EP1224469B1 Method of screening for inhibitors of asp2 |
| 04/06/2005 | EP1218494B1 Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| 04/06/2005 | EP1212100B1 Delivery system for antidandruff agent |
| 04/06/2005 | EP1140062B1 Treatment of asthma with mek inhibitors |
| 04/06/2005 | EP1113809B1 Pharmaceutical preparation containing a cyclopeptide and a chemotherapeutic agent or an angiogenesis inhibitor |
| 04/06/2005 | EP1077700B1 BENZIMIDAZOLE DERIVATIVES AS MODULATORS OF IgE |
| 04/06/2005 | EP0824594B1 Improved methods for transfecting t cells |
| 04/06/2005 | CN1605027A Methods and compositions for treatment of central nervous system disorders |
| 04/06/2005 | CN1604966A Direct targeting binding proteins |
| 04/06/2005 | CN1604910A Affinity enhancement agents |
| 04/06/2005 | CN1604803A Combination of cytochome p450 dependent protease inhibitors |
| 04/06/2005 | CN1604790A Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
| 04/06/2005 | CN1604787A Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI) |
| 04/06/2005 | CN1604779A Novel methods of treating local fungal and bacterial infections |
| 04/06/2005 | CN1604775A Modulation of ocular growth and myopia by GABA drugs |
| 04/06/2005 | CN1603342A Caspase-8 interacting proteins |